โ† Back to Newsletter

USTR Section 301 Determination on Brazil’s Unreasonable Acts, Policies, and Practices

June 01, 2026 ยท USTR Tariff Actions ยท View source โ†—

The Office of the United States Trade Representative (USTR) announced a Section 301 determination regarding Brazil's trade practices on June 1, 2026. This determination addresses what the USTR has identified as Brazilโ€™s unreasonable acts, policies, and practices. Section 301 of the Trade Act of 1974 is a powerful tool that allows the USTR to investigate and respond to foreign government practices that are deemed unfair or discriminatory and that burden or restrict U.S. commerce.

At this time, the specific details of the USTR's findings and any potential actions are not available in the provided information. The announcement title indicates a determination has been made concerning Brazil's "unreasonable acts, policies, and practices," but it does not specify what these practices entail. Consequently, information regarding the particular industries or products that might be affected, any proposed tariff rates, or the effective dates for potential measures has not been released.

For importers, customs brokers, and trade compliance officers engaged in trade with Brazil, this determination signals a critical development. While the immediate implications remain undefined, past Section 301 actions have led to significant changes in import duties and trade regulations for goods from targeted countries. Therefore, it is crucial for stakeholders to closely monitor official USTR announcements for forthcoming details.

As more information becomes available, the USTR is expected to publish a detailed notice outlining the specific findings, the scope of any retaliatory actions, and their effective dates. Importers of Brazilian goods should prepare to review these details carefully to assess potential impacts on their supply chains and landed costs. Consulting with legal counsel or trade compliance experts will be essential once the full scope of the determination is published to ensure continued compliance and mitigate any adverse effects.